Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While KPV is investigated as an anti-inflammatory and barrier-protective agent in skin and mucosal models, reducing pro-inflammatory cytokines and promoting tissue repair684, Tesamorelin is FDA-approved to reduce excess visceral adipose tissue in HIV-associated lipodystrophy and is studied for broader body-composition, NAFLD, and cognitive effects via GH/IGF-1 axis modulation1893.
While KPV works as the C-terminal Lys-Pro-Val tripeptide fragment of α-MSH, which exerts potent anti-inflammatory effects largely via inhibition of NF-κB signaling and modulation of cytokine expression, with many actions independent of classical melanocortin receptor activation684, Tesamorelin is a full-length 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoic acid modification that binds GHRHR, activating cAMP/PKA signaling to increase endogenous GH and IGF-1, with improved stability versus native GHRH182893102.
KPV
POMC
Tesamorelin
GHRH
KPV and Tesamorelin are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: KPV is more often discussed in the realm of Immunology and inflammation, Gastroenterology, and Dermatology and aesthetics, whereas Tesamorelin is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. They also influence different molecular systems, with KPV tracking more closely to Melanocortin receptor while Tesamorelin centers more on Growth hormone axis. KPV has a more natural endogenous origin, while Tesamorelin is closer to synthetic analog background and their development context also differs, with KPV in Preclinical development while Tesamorelin is approved. KPV takes the form of a linear peptide, whereas Tesamorelin is closer to a peptide conjugate, Tesamorelin incorporates amidation features that are not part of KPV; while their sequence patterns also diverge, with KPV showing protein-mimetic sequence features and Tesamorelin showing alpha-helical domain features.
No related articles are linked to these peptides yet.